XML 47 R28.htm IDEA: XBRL DOCUMENT v3.19.1
Organization, Basis of Presentation and Liquidity (Tables)
12 Months Ended
Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Biotime's Ownership of Outstanding Shares of Its Subsidiaries

The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of December 31, 2018.

 

Subsidiary   Field of Business   BioTime Ownership     Country
Cell Cure Neurosciences Ltd. (“Cell Cure”)   Products to treat age-related macular degeneration     99% (1)     Israel
ES Cell International Pte. Ltd. (“ESI”)   Stem cell products for research, including clinical grade cell lines produced under cGMP     100%     Singapore
OrthoCyte Corporation (“OrthoCyte”)   Developing bone grafting products for orthopedic diseases and injuries     99.8%     USA

 

(1) Includes shares owned by BioTime and ESI